Details for Patent: 9,023,790
✉ Email this page to a colleague
Which drugs does patent 9,023,790 protect, and when does it expire?
Patent 9,023,790 protects NOXAFIL and is included in one NDA.
This patent has twenty-seven patent family members in twenty countries.
Summary for Patent: 9,023,790
| Title: | Posaconazole intravenous solution formulations stabilized by substituted .beta.-cyclodextrin |
| Abstract: | The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified .beta.-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties. |
| Inventor(s): | Heimbecher; Susan K. (Morris Plains, NJ), Monteith; David (Pittstown, NJ), Pipkin; James D. (Lawrence, KS) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
| Application Number: | 13/704,145 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,023,790 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Use; Device; |
Drugs Protected by US Patent 9,023,790
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER | ⤷ Try a Trial | ||
| Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS | ⤷ Try a Trial | ||
| Merck Sharp Dohme | NOXAFIL | posaconazole | SOLUTION;INTRAVENOUS | 205596-001 | Mar 13, 2014 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,023,790
| PCT Information | |||
| PCT Filed | June 24, 2011 | PCT Application Number: | PCT/US2011/041715 |
| PCT Publication Date: | January 12, 2012 | PCT Publication Number: | WO2012/005973 |
International Family Members for US Patent 9,023,790
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011276680 | ⤷ Try a Trial | |||
| Brazil | 112012033077 | ⤷ Try a Trial | |||
| Canada | 2802929 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
